Okazuka Kiyoshi, Ishida Tadao, Sato Kota, Miyazaki Kanji, Yoshiki Yumiko, Abe Yu, Tsukada Nobuhiro, Suzuki Kenshi
Department of Hematology, Japanese Red Cross Medical Center.
Rinsho Ketsueki. 2018;59(6):698-700. doi: 10.11406/rinketsu.59.698.
Twenty-nine patients with multiple myeloma were treated with carfilzomib, lenalidomide, and dexamethasone (KLd) therapy. A response better than partial response (PR) was observed in 72.4% patients with relapsed and/or refractory myeloma. Although 13.8% patients developed hypertension, none of them discontinued therapy as they could be managed by appropriate medication. A patient who had an elevated level of BNP prior to initiating KLd therapy developed heart failure. Results from this study demonstrate that KLd therapy is efficacious for treating patients with multiple myeloma; however, they should be carefully monitored for cardiotoxicity.
29例多发性骨髓瘤患者接受了卡非佐米、来那度胺和地塞米松（KLd）治疗。在72.4%的复发和/或难治性骨髓瘤患者中观察到优于部分缓解（PR）的反应。虽然13.8%的患者出现了高血压，但他们中没有人因可通过适当药物治疗而停药。1例在开始KLd治疗前脑钠肽（BNP）水平升高的患者发生了心力衰竭。本研究结果表明，KLd治疗对多发性骨髓瘤患者有效；然而，应密切监测患者的心脏毒性。
